Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2015

View Archived Issues

Paradigm Biopharmaceuticals cleared to start clinical trial of Zilosul in BME

Alexar Therapeutics initiates phase IIa trial of ALX-101 for atopic dermatitis

FDA clears University of Minnesota to conduct phase I/II trial of OXS-1550

Kennedy Krieger Institute to study Viking Therapeutics' thyroid beta agonists for X-ALD

NINDS grant to support Aquinnah's development of novel ALS therapies

Almirall announces strategic acquisition of dermatology products

Can-Fite to expand development of CF-102 into NASH

Summit releases promising findings from phase II trial of ridinilazole for C. difficile infection

CytRx reports on progress of phase II trial of aldoxorubicin in glioblastoma

Lysogene's gene therapy receives orphan drug and rare pediatric disease designations

Preclinical results provided for selective PI3K-gamma inhibitor IPI-549

Anti-PDPN MAb ChLpMab-7 shows potential as anticancer therapy

BTK inhibition, a potential strategy for the treatment of lupus nephritis

BIND-510, a vincristine-containing PSMA-targeted Accurin assessed in multiple tumor models

Combination of pembrolizumab and chemotherapy feasible in metastatic cancer

SAR-125844 tolerable, active in phase I study in Asian patients with solid tumors

FDA approves Fluad seasonal influenza vaccine

Global Blood Therapeutics develops kallikrein inhibitors

Kissei Pharmaceutical discloses NK1 receptor antagonists

University of California, Oakland divulges UT-A inhibitors

Bristol-Myers Squibb has patented GPR40 modulators

Infinity Pharmaceuticals introduces PI3K inhibitors

Once-weekly DPP-4 inhibitor Marizev launched in Japan

BioMarin releases FDA advisory committee views on drisapersen NDA data package

Miticure now available in Japan

FDA grants fast track designation to Cellceutix's Brilacidin-OM

European Commission approves Praxbind

Amgen submits BLA for biosimilar adalimumab ABP-501

Cobimetinib approved in E.U. for treatment of melanoma in combination with vemurafenib

EquMet combination tablets launched for T2D in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...